The concept that adult stem cells could be used to regenerate the infarction damaged heart to treat heart failure captured the imagination of both the public and scientific community. This concept dates back 14 years with the first description by Orlic and colleagues that cKit+ cells derived from bone marrow could abundantly transdifferentiate into new contracting myocardium when directly injected into the infarcted heart. Two years later Beltrami and colleagues showed that cKit+ progenitors from the heart itself could be extracted, expanded ex vivo, and reinjected into the rodent heart to again abundantly transdifferentiate and create as much as 70% new contracting myocardium. Fast forward to the present day and the current picture of myocardial regeneration from cKit+ progenitors or some other adult stem cell population seems rather unlikely. This current picture was made even more concrete with the recent publication of yet another definitive in vivo lineage tracing study for cKit+ cells in the heart, by Sultana and colleagues.